Patricia R. Feliciano

Patricia R. Feliciano

Auto-generated profile, based on publicly available information

Patricia R. Feliciano

Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
DLDieter K. Lam
Dieter K. Lam
PFPatricia R. Feliciano
Patricia R. Feliciano
AAAmena Arif
Amena Arif
TBTanggis Bohnuud
Tanggis Bohnuud
TFThomas P. Fernandez
Thomas P. Fernandez
NGNicole M. Gaudelli
Nicole M. Gaudelli
Cytosine base editors (CBEs) enable programmable genomic C·G-to-T·A transition mutations and typically comprise a modified CRISPR–Cas enzyme, a naturally occurring cytidine deaminase, and an inhibitor of uracil repair. Previous studies have shown that CBEs utilizing naturally occurring cytidine deaminases may cause unguided, genome-wide cytosine deamination. While improved CBEs that decrease stochastic genome-wide off-targets have subsequently been reported, these editors can suffer from suboptimal on-target performance. Here, we report the generation and characterization of CBEs that use engineered variants of TadA (CBE-T) that enable high on-target C·G to T·A across a sequence-diverse set of genomic loci, demonstrate robust activity in primary cells and cause no detectable elevation in genome-wide mutation. Additionally, we report cytosine and adenine base editors (CABEs) catalyzing both A-to-I and C-to-U editing (CABE-Ts). Together with ABEs, CBE-Ts and CABE-Ts enable the programmable installation of all transition mutations using laboratory-evolved TadA variants with improved properties relative to previously reported CBEs.

15 August 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PFPatricia R. Feliciano
Patricia R. Feliciano
CDCatherine L. Drennan
Catherine L. Drennan
MNMaria Cristina Nonato
Maria Cristina Nonato
Significance: Leishmaniases, Chagas disease, and sleeping sickness are parasitic diseases classified as neglected tropical diseases, affecting approximately one-sixth of the world’s population. Because of the absence of effective medicines to treat these diseases, there is a substantial interest in the identification of new targets for the development of therapeutic strategies to combat neglected tropical diseases. We have determined the crystal structure of a class I fumarate hydratase (FH) from Leishmania major , the parasite responsible for cutaneous leishmaniasis, and find that the structure is distinct from class II human FH. Thus, Leishmania class I FH, which is an essential metabolic enzyme, offers a new perspective for the development of antileishmaniases therapies.

30 October 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DWDana E. Westmoreland
Dana E. Westmoreland
PFPatricia R. Feliciano
Patricia R. Feliciano
GKGyunghoon Kang
Gyunghoon Kang
CCChang Cui
Chang Cui
AKAlbert Kim
Albert Kim
CDCatherine L. Drennan
Catherine L. Drennan
Ribonucleotide reductases (RNRs) reduce ribonucleotides to deoxyribonucleotides using radical-based chemistry. For class Ia RNRs, the radical species is stored in a separate subunit (β2) from the subunit housing the active site (α2), requiring the formation of a short-lived α2β2 complex and long-range radical transfer (RT). RT occurs via proton-coupled electron transfer (PCET) over a long distance (~32-Å) and involves the formation and decay of multiple amino acid radical species. Here, we use cryogenic electron microscopy and a mechanism-based inhibitor 2′-azido-2′-deoxycytidine-5′-diphosphate (N 3 CDP) to trap a wild-type α2β2 complex of Escherichia coli class Ia RNR. We find that one α subunit has turned over and that the other is trapped, bound to β in a midturnover state. Instead of N 3 CDP in the active site, forward RT has resulted in N 2 loss, migration of the third nitrogen from the ribose C2′ to C3′ positions, and attachment of this nitrogen to the sulfur of cysteine-225. In this study, an inhibitor has been visualized as an adduct to an RNR. Additionally, this structure reveals the positions of PCET residues following forward RT, complementing the previous structure that depicted a preturnover PCET pathway and suggesting how PCET is gated at the α–β interface. This N 3 CDP-trapped structure is also of sufficient resolution (2.6 Å) to visualize water molecules, allowing us to evaluate the proposal that water molecules are proton acceptors and donors as part of the PCET process.

15 January 2019 in ACS Chemical Biology
Verified
Journal Article
Open access
PFPatricia R. Feliciano
Patricia R. Feliciano
CDCatherine L. Drennan
Catherine L. Drennan
MNMaria Cristina Nonato
Maria Cristina Nonato
Leishmaniases affect the poorest people on earth and have no effective drug therapy. Here, we present the crystal structure of the mitochondrial isoform of class I fumarate hydratase (FH) from Leishmania major and compare it to the previously determined cytosolic Leishmania major isoform. We further describe the mechanism of action of the first class-specific FH inhibitor, 2-thiomalate, through X-ray crystallography and inhibition assays. Our crystal structures of both FH isoforms with inhibitor bound at 2.05 Å resolution and 1.60 Å resolution show high structural similarity. These structures further reveal that the selectivity of 2-thiomalate for class I FHs is due to direct coordination of the inhibitor to the unique Fe of the catalytic [4Fe-4S] cluster that is found in class I parasitic FHs but is absent from class II human FH. These studies provide the structural scaffold in order to exploit class I FHs as potential drug targets against leishmaniases as well as Chagas diseases, sleeping sickness and malaria.


17 May 2021 in ACS Omega
Verified
Journal Article
Open access
PFPatricia R. Feliciano
Patricia R. Feliciano
KCKate S. Carroll
Kate S. Carroll
CDCatherine L. Drennan
Catherine L. Drennan
Tuberculosis (TB) is the deadliest infectious disease in the world. In Mycobacterium tuberculosis, the first committed step in sulfate assimilation is the reductive cleavage of adenosine-5′-phosphosulfate (APS) to form adenosine-5′-phosphate (AMP) and sulfite by the enzyme APS reductase (APSR). The vital role of APSR in the production of essential reduced-sulfur-containing metabolites and the absence of a homologue enzyme in humans makes APSR a potential target for therapeutic interventions. Here, we present the crystal structure of the [4Fe–4S] cluster-containing APSR from M. tuberculosis (MtbAPSR) and compare it to previously determined structures of sulfonucleotide reductases. We further present MtbAPSR structures with substrate APS and product AMP bound in the active site. Our structures at a 3.1 Å resolution show high structural similarity to other sulfonucleotide reductases and reveal that APS and AMP have similar binding modes. These studies provide structural data for structure-based drug design aimed to combat TB.